Search Results

LifeMine Therapeutics Inc. today announced the appointment of Jennifer Jarrett to its board of directors.

LifeMine Therapeutics Inc. today announced the appointments of Martin Stahl, Ph.D., as chief scientific officer and Louis Plamondon, Ph.D., as executive vice president and head of CMC. Dr. Stahl, former global head of lead discovery at Roche, will also lead LifeMine’s operations at its European offices in Basel, Switzerland.

LifeMine Therapeutics Inc. announced the appointment of Elliot Ehrich, M.D., as chief medical officer and executive vice president of translational science, and of Lata Jayaraman, Ph.D., as executive vice president and head of biology.

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules from the biosphere, announced a strategic R&D collaboration with GlaxoSmithKline.

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules from the biosphere, announced the completion of a $175 million Series C financing.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

LifeMine Therapeutics Inc, a biopharmaceutical company reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics, today announced the appointment of William G. Kaelin Jr., M.D., to its board of directors. Dr. Kaelin is the Sidney Farber Professor in the Department of Medicine at the Dana-Farber Cancer Institute and at the Brigham and Women’s Hospital at Harvar